Rafa Blanco-Domínguez

Follow the "DOTs": Vδ1⁺ γδ T cells as effectors of #cancer #immunotherapy. New Found in Translation article from Bruno Silva-Santos (@bsilvasantos.bsky.social), Sofia Mensurado, Rafael Blanco-Domínguez (@rafaelblancodom.bsky.social), and Adrian Hayday: rupress.org/jem/article/...

#TumorImmunology

In a new opinion article, Silva-Santos, @rafaelblancodom.bsky.social et al. @gimminstitute.bsky.social discuss the potential of Vδ1⁺ γδ T cells for #cancer #immunotherapy, focusing on delta one T (DOT) cells. rupress.org/jem/article/...

#FoundInTranslation #TumorImmunology

In a new opinion article @jem.org, Silva-Santos, @rafaelblancodom.bsky.social et al. @gimminstitute.bsky.social discuss the potential of Vδ1⁺ γδ T cells for #cancer #immunotherapy, focusing on delta one T (DOT) cells. rupress.org/jem/article/...

#FoundInTranslation #TumorImmunology

A very elegant study. Congratulations!

Incredible! Over the past 2 months, 5 independent manuscripts — from @TheColonnaLab, Dan Littman, @gardnerlabucsf.bsky.social and @chrysothemisbrown.bsky.social , and our own (now in @nature.com, www.nature.com/articles/s41...), reports that the dietary pTreg program is initiated by RORγt⁺ APCs. /1

The unparalleled @bsilvasantos.bsky.social concludes the amazing #gammadeltatoronto with the keynote talk. A moment I've waited for since may2022 inaugural #gdtcellclub talk.

Super excited to see the wrap up for the unbelievable conf thanks to JC and the other fellow organizers.

Let's go!!

Celebrating the #DayofImmunology by spreading the word of DOT cell therapy against CRC at @i3suporto.bsky.social
Thanks for the nice welcoming after an apocalypse-like day in this side of the globe

Meet DOT cells: a Vδ1-biased γδ T cellular product developed by @bsilvasantos.bsky.social team at GIMM with strong antitumor traits. We show they’re powerful CRC killers, especially when combined with the microbiota derivate butyrate or checkpoint (PD1/TIGIT) blockade 🚀Thanks to the whole team!!

Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer Nature Cancer - Silva-Santos and colleagues provide in vivo preclinical evidence supporting a therapeutic use of Delta One T cells to tackle colorectal cancer and propose activating natural killer...

Flying the flag for γδ T cell therapy in colorectal cancer! Our paper is out in @naturecancer.bsky.social: Potent, broad & HLA-independent cytotoxicity & tumor infiltration make DOT cells strong allogeneic candidates against CRC!

rdcu.be/eh0ru

@gimmfoundation.bsky.social
#immunotherapy #gdTcells

Diabetes can impact cellular immunity in solid tumors Cancer is increasingly prevalent worldwide, often coexisting with type 2 diabetes (T2D). Recent breakthroughs reveal the immune system’s pivotal role in eliminating tumors and how the metabolic environment, such as glucose availability, affects antitumor immunity. Diabetes is known to dysregulate both innate and adaptive immune responses, while cancer creates an immunosuppressive microenvironment. We hypothesize that diabetes in cancer subjects may exacerbate this immunosuppression. Here, we examine the current understanding of the interplay between T2D and solid tumors and the associated challenges. Despite inconsistencies in data from mouse models and human tissues, evidence suggests that T2D can impact the antitumor response. Possible mechanisms may involve myeloid cells, inducing local immunosuppression and impairing antigen presentation, and certain lymphoid cell populations, exhibiting exhaustion.

Diabetes can impact cellular immunity in solid tumors #immunology